Scopio Labs team (company pic)
Scopio Labs, an Israeli startup that offers a digital blood test platform, raised $50 million in a Series C financing round from investors including OurCrowd, Aurum Ventures, Mizrahi-Tefahot Bank Invest and Ilex Medical. The investment comes about two years after Scopio raised $16 million in a Series B investment round. The company has now brought in a total of $84 million in investments to date.
Founded in 2015, Scopio Labs offers an advanced cell morphology platform that it says unlocks crucial diagnostic information through full-field scanning and the analysis of thousands of cells, for dramatically faster, earlier and more consistent and accurate detection and disease monitoring.
–
Scopio Labs explains that traditionally, in manual microscopy you have to choose between a large field of view or high resolution. Attempts to digitize cell samples have always faced this frustrating tradeoff. Increasing resolution always meant compromising field of view. Scopio boasts that its innovative imaging technology gives you the big picture and the smallest details at the same time. The tech allows offsite colleagues, hematopathologists and clinicians access to the same browser-based access to the full-field digital image, annotations, and insights as anyone in the lab. Review, collaborate or consult securely from anywhere in real-time.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
“Deep Learning can analyze hundreds of times more healthcare data from a patient, supporting physician decisions and detecting conditions like cancers, anemias, and bleeding disorders, as well as infections and allergies. But for us it all begins with high-quality digital imaging data,” Scopio Labs cofounder and CEO Itai Hayut said in a statement.
“In the 21st century, people shouldn’t be looking through microscopes, manually counting cells. Scopio’s full-field imaging and AI platform means tens of thousands of cells in a single sample can be examined, counted and analyzed instantly and reviewed by a specialist regardless of location, leading to faster, easier and earlier detection and diagnosis of cancers and many other life-threatening medical conditions,” added Hayut about the capabilities of Scopio Labs.
